Reversible Deterioration in Hypophosphatasia Caused by Renal Failure With Bisphosphonate Treatment. (17th August 2015)

• Record Type: Journal Article
• Authors: Cundy, Tim; Michigami, Toshimi; Tachikawa, Kanako; Dray, Michael; Collins, John F; Paschalis, Eleftherios P; Gamsjaeger, Sonja; Roschger, Andreas; Fratzl‐Zelman, Nadja; Roschger, Paul; Klaushofer, Klaus
• Is Part Of: Journal of bone and mineral research. Volume 30:Number 9(2015:Sep.)
• Page Start: 1726
• Page End: 1737
• Publication Date: 2015-08-17
• Subjects: HYPOPHOSPHATASIA -- RENAL FAILURE -- BISPHOSPHONATES -- OSTEOMALACIA -- GENOTYPE‐PHENOTYPE; Bones -- Metabolism -- Periodicals; Mineral metabolism -- Periodicals; 612.392
• DOI: 10.1002/jbmr.2495
• Languages: English
• ISSNs: 0884-0431

Abstract

ABSTRACT: Hypophosphatasia is an inborn error of metabolism caused by mutations in the ALPL gene. It is characterized by low serum alkaline phosphatase (ALP) activity and defective mineralization of bone, but the phenotype varies greatly in severity depending on the degree of residual enzyme activity. We describe a man with compound heterozygous mutations in ALPL, but no previous bone disease, who suffered numerous disabling fractures after he developed progressive renal failure (for which he eventually needed dialysis treatment) and was prescribed alendronate treatment. A bone biopsy showed marked osteomalacia with low osteoblast numbers and greatly elevated pyrophosphate concentrations at mineralizing surfaces. In vitro testing showed that one mutation, T117H, produced an ALP protein with almost no enzyme activity; the second, G438S, produced a protein with normal activity, but its activity was inhibited by raising the media phosphate concentration, suggesting that phosphate retention (attributable to uremia) could have contributed to the phenotypic change, although a pathogenic effect of bisphosphonate treatment is also likely. Alendronate treatment was discontinued and, while a suitable kidney donor was sought, the patient was treated for 6 months with teriparatide, which significantly reduced the osteomalacia. Eighteen months after successful renal transplantation, the patient was free of symptoms and the scintigraphic bone lesions had resolved. A third bone biopsy showed marked hyperosteoidosis but with plentiful new bone formation and a normal bone formation rate. This case illustrates how pharmacological (bisphosphonate treatment) and physiologic (renal failure) changes in the "environment" can dramatically affect the phenotype of a genetic disorder. © 2015 American Society for Bone and Mineral Research. © 2015 American Society for Bone and Mineral Research.